In this video, Motley Fool health-care analyst David Williamson takes a closer look at what has propelled Aegerion Pharmaceuticals (NASDAQ: AEGR) to new heights and what it means for its potential competitor Isis Pharmaceuticals (IONS 1.11%). He also discusses Merck's (MRK 3.32%) latest stumble, a failed study that may get an approved drug pulled from the market.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The stock is hitting new 52-week highs post FDA approval.
David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid.
The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Merck
MRK
$81.78
(3.32%)
$2.62
Sanofi
SNY
$49.02
(1.47%)
$0.71
Ionis Pharmaceuticals
IONS
$39.95
(1.11%)
$0.44
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why AstraZeneca Stock Topped the Market on Tuesday
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money.
Great News for Hims & Hers Stock Investors
2 Stocks That Have Doubled This Year and Are Still Worth Buying
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.